Zacks Research Issues Positive Outlook for CORT Earnings

by · The Cerbat Gem

Corcept Therapeutics Incorporated (NASDAQ:CORT – Free Report) – Research analysts at Zacks Research lifted their Q2 2025 earnings per share (EPS) estimates for Corcept Therapeutics in a note issued to investors on Wednesday, March 19th. Zacks Research analyst K. Das now expects that the biotechnology company will post earnings per share of $0.37 for the quarter, up from their prior forecast of $0.34. The consensus estimate for Corcept Therapeutics’ current full-year earnings is $1.36 per share. Zacks Research also issued estimates for Corcept Therapeutics’ Q3 2025 earnings at $0.47 EPS, FY2025 earnings at $1.64 EPS, Q2 2026 earnings at $0.67 EPS, Q3 2026 earnings at $0.82 EPS, Q4 2026 earnings at $0.89 EPS, FY2026 earnings at $2.83 EPS and FY2027 earnings at $3.81 EPS.

Several other research analysts have also weighed in on CORT. HC Wainwright reissued a “buy” rating and issued a $115.00 price objective on shares of Corcept Therapeutics in a research report on Thursday, February 27th. Piper Sandler lifted their target price on Corcept Therapeutics from $67.00 to $78.00 and gave the stock an “overweight” rating in a report on Thursday, February 27th. Canaccord Genuity Group increased their price target on Corcept Therapeutics from $78.00 to $130.00 and gave the stock a “buy” rating in a report on Thursday, January 30th. Finally, StockNews.com lowered shares of Corcept Therapeutics from a “buy” rating to a “hold” rating in a research note on Friday, February 28th. One equities research analyst has rated the stock with a hold rating and five have assigned a buy rating to the company. According to data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average price target of $99.75.

Get Our Latest Report on Corcept Therapeutics

Corcept Therapeutics Price Performance

Shares of NASDAQ CORT opened at $57.59 on Friday. The company has a quick ratio of 3.64, a current ratio of 3.70 and a debt-to-equity ratio of 0.01. The company has a market capitalization of $6.08 billion, a PE ratio of 45.71 and a beta of 0.61. The firm has a fifty day simple moving average of $61.32 and a 200 day simple moving average of $53.51. Corcept Therapeutics has a twelve month low of $20.84 and a twelve month high of $75.00.

Corcept Therapeutics (NASDAQ:CORT – Get Free Report) last released its quarterly earnings results on Wednesday, February 26th. The biotechnology company reported $0.26 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.37 by ($0.11). Corcept Therapeutics had a return on equity of 24.54% and a net margin of 22.35%. The firm had revenue of $181.89 million for the quarter, compared to the consensus estimate of $200.12 million.

Institutional Inflows and Outflows

A number of large investors have recently modified their holdings of CORT. Kestra Investment Management LLC purchased a new stake in Corcept Therapeutics in the 4th quarter valued at $27,000. Canada Pension Plan Investment Board bought a new stake in shares of Corcept Therapeutics in the 4th quarter worth $40,000. National Bank of Canada FI purchased a new stake in shares of Corcept Therapeutics in the fourth quarter valued at about $42,000. USA Financial Formulas bought a new position in shares of Corcept Therapeutics during the fourth quarter valued at about $54,000. Finally, Newbridge Financial Services Group Inc. purchased a new position in Corcept Therapeutics during the fourth quarter worth about $58,000. Institutional investors own 93.61% of the company’s stock.

Insider Buying and Selling at Corcept Therapeutics

In related news, CEO Joseph K. Belanoff sold 2,924 shares of the company’s stock in a transaction dated Monday, March 3rd. The shares were sold at an average price of $60.91, for a total value of $178,100.84. Following the sale, the chief executive officer now owns 3,019,411 shares in the company, valued at $183,912,324.01. This represents a 0.10 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Also, Director Daniel N. Swisher, Jr. sold 2,200 shares of Corcept Therapeutics stock in a transaction dated Friday, January 10th. The shares were sold at an average price of $50.54, for a total value of $111,188.00. The disclosure for this sale can be found here. Over the last quarter, insiders sold 45,627 shares of company stock valued at $2,557,674. Company insiders own 20.50% of the company’s stock.

About Corcept Therapeutics

(Get Free Report)

Corcept Therapeutics Incorporated engages in discovery and development of drugs for the treatment of severe endocrinologic, oncologic, metabolic, and neurologic disorders in the United States. It offers Korlym tablets medication for the treatment of hyperglycemia secondary to hypercortisolism in adult patients with endogenous cushing's syndrome; and who have type 2 diabetes mellitus or glucose intolerance and have failed surgery or are not candidates for surgery.

Featured Stories